IL108719A0 - Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them - Google Patents

Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them

Info

Publication number
IL108719A0
IL108719A0 IL10871994A IL10871994A IL108719A0 IL 108719 A0 IL108719 A0 IL 108719A0 IL 10871994 A IL10871994 A IL 10871994A IL 10871994 A IL10871994 A IL 10871994A IL 108719 A0 IL108719 A0 IL 108719A0
Authority
IL
Israel
Prior art keywords
retroviralvectors
nucleotide sequences
expression constructs
recombinant retroviruses
hiv inhibitory
Prior art date
Application number
IL10871994A
Other languages
English (en)
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of IL108719A0 publication Critical patent/IL108719A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
IL10871994A 1993-02-25 1994-02-21 Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them IL108719A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2193693A 1993-02-25 1993-02-25
US19035094A 1994-02-01 1994-02-01

Publications (1)

Publication Number Publication Date
IL108719A0 true IL108719A0 (en) 1994-08-26

Family

ID=26695271

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10871994A IL108719A0 (en) 1993-02-25 1994-02-21 Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them

Country Status (6)

Country Link
EP (1) EP0612844A2 (xx)
JP (1) JPH06335392A (xx)
KR (1) KR940019314A (xx)
AU (1) AU5639494A (xx)
FI (1) FI940867A (xx)
IL (1) IL108719A0 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018854A1 (en) * 1994-01-05 1995-07-13 Gene Shears Pty., Ltd. Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
AU2133695A (en) * 1994-04-06 1995-10-30 Sadna Joshi-Sukhwal Inhibition of hiv-1 multiplication in mammalian cells
US20020058636A1 (en) * 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
EP1380650B1 (en) * 1995-11-28 2010-01-20 The Johns Hopkins University School Of Medicine Conditionally replicating viral vectors and their use
US5885806A (en) * 1995-11-28 1999-03-23 The Johns Hopkins University School Of Medicine Methods to prepare conditionally replicating viral vectors
EP0914423A2 (en) * 1996-06-06 1999-05-12 Novartis AG Inhibition of hiv-1 replication by antisense rna expression
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US7244570B2 (en) 1998-08-04 2007-07-17 Luminex Molecular Diagnostics, Inc. Methods and compositions for modulating “marginally indiscriminant” hybridizations
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
CA2352532C (en) 1998-11-27 2014-10-14 Darwin Discovery Ltd. Compositions and methods for increasing bone mineralization
US7063850B1 (en) 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
EP1179082A2 (en) * 1999-05-21 2002-02-13 Oxford Biomedica (UK) Limited Improved retroviral production by inhibition of the enveloppe cell receptor
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
CA2446112C (en) 2001-05-08 2011-04-26 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein
US7345025B2 (en) 2001-07-10 2008-03-18 Johnson & Johnson Research Pty. Limited Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
US7994144B2 (en) 2001-07-10 2011-08-09 Johnson & Johnson Research Pty, Limited Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
CA2464527A1 (en) 2001-10-26 2003-08-14 Id Biomedical Corporation Of Washington Multivalent streptococcal vaccine compositions and methods for use
WO2021211952A2 (en) * 2020-04-16 2021-10-21 Massachusetts Institute Of Technology Compositions and methods for sequestering viruses

Also Published As

Publication number Publication date
EP0612844A2 (en) 1994-08-31
JPH06335392A (ja) 1994-12-06
KR940019314A (ko) 1994-09-14
FI940867A (fi) 1994-08-26
AU5639494A (en) 1994-09-01
FI940867A0 (fi) 1994-02-24

Similar Documents

Publication Publication Date Title
IL108719A0 (en) Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
AU4214289A (en) Viral nucleotide sequences
CA2153254A1 (en) Cloning of enterokinase and method of use
EP0968224A4 (en) CHIMERIC MUTATIONAL VECTORS WITH NON-NATURAL NUCLEOTIDES
CA2296769A1 (en) Modified dorsal tissue affecting factor and compositions
CA2165821A1 (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
EP0658627A3 (en) DNA recombined with the alpha interferon promoter.
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
AU4556589A (en) Extended nucleotide sequences
EP0670895A4 (en) CLONING, EXPRESSION AND USES OF A NEW SECRETIED PROTEIN, F-SPONDIN.
WO1994005791A3 (en) Dorsal tissue affecting factor and compositions
ZA965342B (en) Beta-xylosidase nucleotide sequence encoding it and use thereof
AU5675794A (en) Mucosal vascular addressin, dna and expression
AU7102594A (en) Oligonucleotides which inhibit hiv protease function
EP0660643A3 (en) Heating element in ceramic fibers.
AU2690595A (en) Isolated dna encoding c-(mer) protooncogene
IL108148A0 (en) Toothbrushes, particularly for one-time use
AU2587495A (en) Vectors with multiple HIV-1 tar sequences inhibiting HIV-1 gene expression
ZA941287B (en) Expression constructs containing HIV inhibitory antisense and other nucleotide sequences, retroviral vectors and recombinant retroviruses containing same.
AU4751990A (en) Nucleotides encoding human b1, 4-galactosyltransferase and uses thereof
AU4100793A (en) Homology cloning
PH31659A (en) Therapeutic nucleotides.
EP0584365A4 (en) NEW AGENT FOR HAIR GROWTH AND GROWTH.
IL80559A0 (en) Streptomycin sensitive gene having many cloning sites,plasmid vector containing the same and microorganism containing the vector
AU2148192A (en) Cloning and/or expression vectors, preparation and use